Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.41 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975182 | 1.00 | SLC1A2 (0.45) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL21853764 | 1.00 | SLC1A2 (0.45) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL26087228 | 0.81 | SLC1A2 (0.45) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL11606505 | 0.79 | TSHR (0.50) | ACP3NR1I2CYP3A4LMNABLM | |
| SCHEMBL13957618 | 0.79 | LMNA (0.43) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL6322741 | 0.79 | MEN1 (0.59) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL29400420 | 0.79 | MEN1 (0.59) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL753104 | 0.79 | MEN1 (0.59) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL1159922 | 0.79 | MEN1 (0.59) | SLC1A2SLC1A3SLC1A1MEN1KMT2A | |
| SCHEMBL29122982 | 0.79 | MEN1 (0.59) | SLC1A2SLC1A3SLC1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630795-B1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | ENZYMASTER NINGBO BIO ENG CO LTD (CN) | 2023-07-26 | — | — | EP | disclosed |
| CN-110869383-B | Engineered polypeptides and their use in the synthesis of beta-hydroxy-alpha-amino acids | 宁波酶赛生物工程有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110914288-B | Engineered aldolase polypeptides and uses thereof | 宁波酶赛生物工程有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2022-03-15 | — | — | US | disclosed |
| US-20210284987-A1 | ENGINEERED POLYPEPTIDES AND THEIR APPLICATIONS IN THE SYNTHESIS OF BETA-HYDROXY-ALPHA-AMINO ACIDS | ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) | 2021-09-16 | — | — | US | disclosed |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-04-23 | — | — | US | disclosed |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-04-23 | — | — | US | disclosed |
| CN-110914288-A | Engineered aldolase polypeptide and application thereof | 宁波酶赛生物工程有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110869383-A | Engineered polypeptide and application thereof in synthesis of β -hydroxy- α -amino acid | 宁波酶赛生物工程有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274287-B2 | Engineered aldolase polypeptides and uses thereof | DERA, ALDOA, TKT | SLC1A2 279/4885SLC1A3 390/4885SLC1A1 372/4885 |
| US-20200123525-A1 | ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF | DERA, ALDOA, TKT | SLC1A2 279/4885SLC1A3 390/4885SLC1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.